Zeidan AM,Platzbecker U,Bewersdorf JP,Stahl M,Ades L,Borate U .2023 .Consensus proposal for revised international working group 2023 response criteria for higher-risk myelodysplastic syndromes. Blood, 10(17) : 2047-61.
Ho FW,Madanat YF .2023 .Molecular drivers of myelodysplastic neoplasms (MDS) classi cation and prognostic relevance. Cells, 10(4) : 627.
Srilakshmi K,Lakshmi DV .2024 .Myelodysplastic syndrome risk assessment using priority linked correlated feature set using ResNet50. Biomed Signal Proc Control, 106597(8) : 106597.
Kewan T,Stahl M,Bewersdorf JP,Zeidan AM .2024 .Treatment of myelodysplastic syndromes for older patients: Current state of science, challenges, and opportunities. Curr Hematol Malig Rep, 10(3) : 151.
Auger N,Guilbert ND,Quessada J,Theisen O,Pochitalo ML,Troadec MB .2023 .Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogenetique hematologique (GFCH). Curr Res Transl Med, 103409(4) : 103409.
Ra N,Khan MH,Sahibzada M,Khan SA,Vijayan AS,Ullah N .2024 .Recent developments and challenges in the treatment of acute leukemia and myelodysplastic syndromes: A systematic review. Cureus, 10(10) : .
Khanna V,Lu R,Kumar J,Stehr H,Spinner MA,Silva O .2022 .Characterization of clinical, molecular, and prognostic features of the WHO 2022 classi cation system for myelodysplastic neoplasms (MDS). Blood, 10 : 6955-7.
Mahmood R,Altaf C,Ahmed P,Khan SA,Malik HS .2017 .Myelodysplastic syndrome in Pakistan: Clinicohematological characteristics, cytogenetic pro le, and risk strati cation. Turk J Haematology, 0130(2) : 109-55.
Arber DA,Orazi A,Hasserjian R,Thiele J,Borowitz MJ,Le Beau MM .2016 .The 2016 revision to the World Health Organization classi cation of myeloid neoplasms and acute leukemia. -03-643544., 10(20) : 2391-405.
Baer C,Huber S,Hutter S,Meggendorfer M,Nadarajah N,Walter W .2023 .Risk prediction in MDS: Independent validation of the IPSS-M ready for routine?. Leukemia, 10(4) : 938-41.
Anwar N,Arshad A,Nadeem M,Khurram S,Fatima N,Sharif S .2017 .cytogenetic pro le of myelodysplastic syndromes in Pakistan-compare and contrast. Mol Cytogenet, 10 : 1-7.
Rashid A,Khurshid M,Shaikh U,Adil S U .2014 .Chromosomal abnormalities in primary myelodysplastic syndrome. J Coll Physicians Surg Pak, 24(9) : 632.
Sultan S,Irfan SM .2016 .Adult primary myelodysplastic syndrome: experience from a tertiary care center in Pakistan. Asian Pac J Can Prev, 17(3) : 1535-7.
Narayanan S. .2017 .Clinical, hematological, and cytogenetic pro le of adult myelodysplastic syndrome in a tertiary care center. J Blood Med, 10 : 21-7.
Voso MT,Fenu S,Latagliata R,Buccisano F,Piciocchi A,Spiriti MAA .2012 .Revised international prognostic scoring system (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes signi cantly better than IPSS and WHO prognostic scoring system: Validation by the gruppo romano mielodisplasie Italian regional database. J Clin Oncol, 48(21) : 2671-7.
Greenberg PL,Tuechler H,Schanz J,Sanz G,Manero GG,Sole F .2012 .Revised international prognostic scoring system for myelodysplastic syndromes. -03-420489., 10(12) : 2454-65.
Chaubey R,Sazawal S,Dada R,Mahapatra M,Saxena R .2011 .Cytogenetic pro le of Indian patients with de novo myelodysplastic syndromes. Indian J Med Res, 134(4) : 452-7.
Wu J,Zhang Y,Qin T,Xu Z,Qu S,Pan L .2022 .IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons e60 years with myelodysplastic syndromes. Exp Hematol Oncol, 10(1) : 73.
Hou HA,Tsai CH,Lin CC,Chou WC,Kuo YY,Liu CY .2018 .Incorporation of mutations in ve genes in the revised international prognostic scoring system can improve risk strati cation in the patients with myelodysplastic syndrome. Blood Can J, 10(4) : 39.
Elnahass Y,Youssif L Y .2018 .Cytogenetic features in primary myelodysplastic syndrome Egyptian patients. J Adv Res, 02 : 77-83.
Li L,Liu X-P,Nie L,Yu M-H,Zhang Y,Qin T-J .2008 .Unique cytogenetic features of primary myelodysplastic syndromes in Chinese patients. Leukemia Res, 11(9) : 1194-8.